Drug intelligence / Profile preview

KIMS-001

Development stage: Preclinical
Lead developer: Kims Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

KIMS-001 is an incrementally modified drug (IMD) under development by Kims Pharmaceutical for the treatment of rheumatoid arthritis. Classified as an IMD, the candidate is designed as an optimized version of an existing therapeutic, potentially featuring a modified formulation or salt to enhance clinical outcomes or patient adherence. The program is currently in the preclinical research phase.

Targets

TRPV3 (Transient receptor potential vanilloid subtype 3)

Beyond the preview

Go deeper on KIMS-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIMS-001.

Explore the full profile